Celcuity Inc. — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This annual filing does not provide standalone fourth-quarter results. Celcuity is a pre-revenue cellular-analysis and diagnostics company developing its CELx platform. The financial statements received an unmodified audit opinion.
Key financial results
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue to date |
| Research and development | $4.98 million | $3.06 million | Up 63% |
| General and administrative | $0.97 million | $0.26 million | Up 269% |
| Total operating expenses | $5.95 million | $3.33 million | Up 79% |
| Net loss | $6.25 million | $3.31 million | Loss widened 89% |
| Net loss per share | $0.84 | $0.52 | Loss per share increased |
| Cash used in operating activities | $4.95 million | $2.89 million | Use increased |
Margins are not meaningful because the company had no revenue. Interest expense was $0.45 million in 2017, primarily from financing costs and discount amortization on convertible notes; interest income was $0.15 million.
At year-end, total assets were $31.97 million, including $2.64 million of cash and cash equivalents and $28.76 million of investments. Current liabilities totaled $0.58 million, with no debt reported on the balance sheet. Stockholders’ equity was $31.39 million. The company reported $31.4 million of cash, cash equivalents and investments combined.
Business and material developments
- CELx tests use living tumor cells to assess signaling activity and drug response. The first test, CELx HER2 Signaling Function (HSF), is analytically validated and commercially ready as a laboratory-developed test; the company had not generated test-sale revenue.
- Celcuity is conducting a 54-patient clinical trial with NSABP, with Genentech supplying HER2-targeted drugs. Celcuity funds patient-related study costs. The company expected interim results in late 2018 and final results six to nine months later.
- The company reported identifying 14 additional potential cancer sub-types across several cancer types; related tests remain in development.
- In September 2017, Celcuity completed its IPO, selling 2.76 million shares at $9.50 per share for approximately $23.3 million in net proceeds. Convertible notes converted into common stock upon the IPO. The company’s Minnesota LLC converted to a Delaware corporation.
- Operating expenses increased substantially, reflecting higher R&D compensation, validation and clinical-trial preparation, patent costs, stock-based compensation, and public-company expenses.
Liquidity, outlook and risks
Management stated that available cash was expected to fund operations and obligations for at least the next 24 months, based on its current business plan. Spending was expected to rise as the company develops tests, conducts clinical trials, expands infrastructure and begins commercialization. The company may seek further financing; additional capital may be unavailable or could dilute shareholders or impose restrictive terms.
Key uncertainties include clinical-trial enrollment and results, pharmaceutical partnerships, future regulatory requirements for laboratory-developed tests, market adoption and reimbursement, and the company’s ability to commercialize its tests. Other disclosed risks include competition, reliance on a single laboratory, intellectual-property challenges, and the need to build commercial capabilities. Celcuity disclosed no material legal proceedings and no off-balance-sheet arrangements. It did not expect to pay dividends in the foreseeable future.
The NSABP study was estimated to cost $2.65 million, subject to adjustment; additional patient-related payments were also described in the commitments note. The filing describes the clinical-trial obligation using different payment estimates and terms, so investors should review the agreement and note disclosures for the definitive remaining commitment.
Important facts for investors to verify
- Clinical-trial enrollment, timing, and results for the CELx HSF study, including whether results support the test’s use as a companion diagnostic.
- Cash burn and runway against the stated 24-month funding expectation, including clinical-trial and planned facility costs.
- Exact remaining clinical-trial payment obligations and any changes to the study budget or timeline.
- Whether pharmaceutical partnerships, test sales, regulatory pathways, and reimbursement develop as management anticipates; the stated $4,000–$7,000 test price was an estimate, not demonstrated realized pricing.
- Share dilution from equity compensation, warrants, and any future financing; year-end common shares outstanding were 10,087,516.